The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

Enlarged illustration of 2 OTEZLA® (apremilast) 30 mg tablets surrounded by 5 people in various activities

RESULTS: THE WAY THEY WANT THEM

BROAD AND SUSTAINED EFFICACY

  • The only oral treatment to deliver efficacy across 6 key manifestations of psoriatic arthritis1-6
    • Tender and swollen joints
    • Dactylitis
    • Enthesitis
    • Axial symptoms*
    • Skin psoriasis
    • Nail psoriasis

PROVEN LONG-TERM SAFETY

  • Well tolerated for up to 4 years7
  • Proven long-term safety profile7,8
  • No label-required laboratory monitoring8

EASE OF USE8

  • Convenient, oral dosing
  • Unique mechanism in psoriatic arthritis treatment—oral intracellular PDE4 inhibitor

*As assessed by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).

References:

  1. Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016-2029.
  2. Kavanaugh A, Gladman DD, Gomez-Reino JJ, et al. Long-term (156-Week) Efficacy and Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial and Open-label Extension (PALACE 1). Long-term (156-Week) Efficacy and Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial and Open-label Extension (PALACE 1). Presented at: the Annual European Congress of Rheumatology EULAR 2016; 8–11 June 2016; London, UK. 2016.
  3. Cutolo M, Mease PJ, Gladman D, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in tender and swollen joint counts in patients with psoriatic arthritis: results from three phase 3, randomized, controlled trials. Presented at: the 2013 ACR/ARHP Annual Meeting; October 26–30, 2013; San Diego, CA. Abstract 317.
  4. Mease PJ, Marzo-Ortega H, Poder A, et al. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-term (52-Week) Improvements in BASDAI in Patients With Psoriatic Arthritis: Pooled Results From 3 Phase III, Randomized, Controlled Trials. Presented at: the Annual European Congress of Rheumatology EULAR 2016; 8–11 June 2016; London, UK.
  5. Gladman DD, Kavanaugh A, Adebajo AO, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (104-week) improvements in enthesitis and dactylitis in patients with psoriatic arthritis: pooled results from three phase III, randomized, controlled trials. Presented at: the 2015 ACR/ARHP Annual Meeting; November 7–11, 2015; San Francisco, CA. Abstract 2888.
  6. Edwards CJ, Blanco FJ, Crowley J, et al. Efficacy of Long-term (104-Week) Treatment With Apremilast in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial and Open-Label Extension. Presented at: the 74th Annual Meeting of the American Academy of Dermatology; March 4-8, 2016; Washington, DC.
  7. Mease PJ, Gladman DD, Gomez-Reino JJ, et al. Consistent safety profile with up to 4 years of apremilast treatment: analysis of data from 1,493 subjects with psoriatic arthritis in 3 large, phase III, long-term studies. Presented at: the 2017 ACR/ARHP Annual Meeting; November 3-8, 2017; San Diego, CA.
  8. OTEZLA Summary of Product Characteristics. Amgen Europe B.V. Minervum 7061, 4817 ZK Breda, The Netherlands; 2020
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.